Key Takeaways Continued dependence on a single drug and declining new enrollments could limit future revenue growth and expose the company to market and patent risks. Rising operational costs, increased R&D spending, and industry pressures on pricing may further constrain profitability and long-term earnings potential.Read more
Key Takeaways Heavy dependence on a single aging product leaves Puma vulnerable to generic competition and shifts in physician treatment preferences. Mounting pricing pressures, regulatory costs, and weak pipeline advancement threaten revenue growth and long-term profitability.Read more
Key Takeaways Precision medicine and biomarker-driven drug development boost clinical success, enable premium pricing, and structurally support higher margins while de-risking future revenue. Robust growth in oncology, expanding NERLYNX franchise, and disciplined financial strategy position Puma for sustained market leadership and efficient portfolio expansion.Read more
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
